Table 1

Increased survival and extended postexposure treatment window in guinea pigs

ExptTreatment (amt in mg)Time of treatment (d.p.i.) with:Mean time to death ± SD (no. of animals that died)No. of survivors/total no. in groupcP valuedAvg wt loss (%)e
DEF201aMAbsb
1PBS7.17 ± 0.75 (6)0/6NAf18
MAbs only (10)39.75 ± 0.96 (4)2/68.00E−048
DEF201 only110.33 ± 1.03 (6)0/68.00E−0425
AdHu5-lacZ+MAbs (10)3311.50 ± 3.70 (4)2/68.00E−04<5
DEF201+MAbs (10)33NA6/68.00E−04<5
DEF201+MAbs (10)4414.33 ± 2.08 (3)3/68.00E−0410
2PBS7.33 ± 0.82 (6)0/6NA16
AdHu5-lacZ+MAbs (10)167.50 ± 0.84 (6)0/67.37E−0122
DEF201+MAbs (10)14NA6/61.00E−03<5
DEF201+MAbs (10)15NA6/61.00E−03<5
DEF201+MAbs (10)16NA6/61.00E−038
DEF201+MAbs (10)17NA6/61.00E−0316
DEF201+MAbs (10)1814 (1)5/61.00E−0321
3PBS7.33 ± 1.21 (6)0/6NA15
DEF201 only210.17 ± 0.75 (6)0/61.30E−0330
DEF201+MAbs (10)24NA6/66.00E−04<5
DEF201+MAbs (10)25NA6/66.00E−047
DEF201+MAbs (10)2610.25 ± 1.71 (4)2/62.90E−0323
4PBS7.50 ± 0.55 (6)0/6NA16
MAbs only (5)39.17 ± 2.14 (6)0/65.53E−0231
DEF201+MAbs (5)3311.60 ± 2.19 (5)1/69.00E−0421
DEF201+MAbs (5)238 (1)5/63.40E−035
DEF201+MAbs (5)13NA6/69.00E−04<5
DEF201+MAbs (5)14NA6/69.00E−04<5
DEF201+MAbs (5)15NA6/69.00E−04<5
DEF201+MAbs (5)1614 (1)5/69.00E−049
  • a Guinea pigs were treated intramuscularly with DEF201 or AdHu5-lacZ (2 × 108 PFU) at the indicated number of days postinfection (d.p.i.) with 1,000× LD50 of GA-ZEBOV.

  • b Guinea pigs were treated intraperitoneally with 5 or 10 mg total MAbs at the indicated d.p.i.

  • c Survival rates on day 28 after challenge.

  • d The log-rank (Mantel-Cox) test was used to calculate the P values. All treatment groups were compared to the corresponding PBS control group.

  • e Average of the maximum weight loss from the original weights on the challenge date.

  • f NA, not applicable.